Advancing the characterization of enlarging lesions after stereotactic radiosurgery: The combined role of clinical timing and dosimetric profiles in distinguishing radiation necrosis from tumor recurrence
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
The distinction between radiation necrosis (RN) and local recurrence (LR) after stereotactic radiosurgery (SRS) has never been more critical: the growing number of long‑term survivors and the increasingly widespread use of radiosurgery are multiplying the cases of enlarging lesions with uncertain etiology, making an updated clarification of clinical and dosimetric criteria essential. SRS has become a mainstay in the treatment of brain metastases, providing excellent local control while limiting neurocognitive toxicity compared with whole‑brain radiotherapy. However, as more patients are treated, radiographic post‑treatment changes have correspondingly increased, and they remain difficult to interpret even with advanced imaging. Despite progress in advanced MRI, amino‑acid PET, and radiomics, biopsy remains the reference standard, an invasive solution that is not always feasible. In this issue of Neuro‑Oncology Practice, Gonzalez et al1 offer one of the broadest and most robust contributions to date to identify clinical and dosimetric factors associated with RN versus LR. Their retrospective analysis of 151 progressive lesions with histologic confirmation represents one of the largest available cohorts. The authors identify age ≥65 years, SRS‑to‑biopsy interval ≥9 months, and higher V12Gy as independent predictors of RN. These results confirm and strengthen previous observations while providing a more robust predictive framework for clinical practice.
Fields of Study & Subjects
Brain Metastases and Treatment
Management of metastatic bone disease
Glioma Diagnosis and Treatment
Publication details
- Journal / source
- Neuro-Oncology Practice
- Volume
- 13
- Issue
- 3
- Pages
- 435–437
- Publication date
- 1 April 2026
- Language
- EN